Coloplast A/S (CLPBY) Stock Forecast & Price Target

$11.13 -0.03 (-0.27%)

As of 02/21/2025 03:59 PM Eastern

Coloplast A/S - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 3 Analyst Ratings

Sell
0

Hold
2

Buy
1

Based on 3 Wall Street analysts who have issued ratings for Coloplast A/S in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a strong buy rating for CLPBY.

Consensus Price Target

N/A

Get the Latest News and Ratings for CLPBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Coloplast A/S and its competitors.

CLPBY Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	1 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	N/A	N/A	N/A	N/A
Forecasted Upside	N/A	N/A	N/A	N/A
Consensus Rating	Moderate Buy	Hold	Hold	Hold

CLPBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CLPBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Coloplast A/S Stock vs. The Competition

Type	Coloplast A/S	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	N/A	29,257.95% Upside	14.36% Upside
News Sentiment Rating	Neutral News See Recent CLPBY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating
1/28/2025	Sanford C. Bernstein 3 of 5 stars	L. Clive Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
12/11/2024	UBS Group 4 of 5 stars	G. Doyle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
11/18/2024	Hsbc Global Res 0 of 5 stars	S. Gupta Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Sell ➝ Hold
9/7/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Perform
9/5/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
7/10/2023	DNB Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
6/1/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight
5/12/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underweight
3/29/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:55 AM ET.

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, February 15, 2025. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

Coloplast A/S
Bull Case

Here are some ways that investors could benefit from investing in Coloplast A/S:

Coloplast A/S has shown a significant drop in short interest, decreasing by 16.3% recently. This indicates a growing confidence among investors, as a lower short interest often suggests that fewer investors are betting against the stock.
The company operates in a stable and growing industry, focusing on intimate healthcare products, which are essential and often in demand regardless of economic conditions. This can provide a level of security for investors.
Coloplast A/S offers a diverse range of innovative products, including the latest SenSura Mio ostomy care solutions and SpeediCath catheters, which cater to various healthcare needs, potentially driving sales growth.
The current stock price of Coloplast A/S is relatively attractive, especially considering its strong market position and product offerings, making it a potentially good entry point for new investors.
The company has a solid track record of financial performance, which can be appealing to investors looking for stability and growth in their portfolios.

Coloplast A/S
Bear Case

Investors should be bearish about investing in Coloplast A/S for these reasons:

Despite the recent drop in short interest, the overall market sentiment can still be volatile, and any negative news could impact the stock price significantly.
Coloplast A/S operates in a highly competitive market, which may pressure profit margins and limit growth opportunities compared to less competitive sectors.
The company’s reliance on specific product lines, such as ostomy and continence care, could pose risks if market demand shifts or if new competitors emerge with superior products.
Regulatory changes in the healthcare industry can affect product approvals and market access, potentially impacting sales and profitability.
Investors should consider the potential for economic downturns, which could lead to reduced healthcare spending and affect Coloplast A/S's revenue streams.

CLPBY Forecast - Frequently Asked Questions

: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coloplast A/S in the last twelve months. There are currently 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CLPBY shares.
: According to analysts, Coloplast A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Coloplast A/S's stock had 2 upgrades by analysts.
: Coloplast A/S has been rated by research analysts at Sanford C. Bernstein, and UBS Group in the past 90 days.
: Analysts like Coloplast A/S less than other "medical" companies. The consensus rating score for Coloplast A/S is 2.67 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CLPBY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (OTCMKTS:CLPBY) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coloplast A/S (CLPBY) Stock Forecast & Price Target